Total
0
Shares
Innocan Pharma - CEO Iris Bincovish
CEO Iris Bincovish
Source: Innocan Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Innocan Pharma (INNO) is pleased to announce the full exercise of all purchase warrants issued during the company’s December 2020 private placement
  • Innocan received approximately $1.4 million from the warrants and issued 3,998,705 common shares
  • Innocan Pharma is a pharmaceutical tech company
  • InnoCan Pharma Corporation (INNO) opened trading at C$0.81 per share

Innocan Pharma (INNO) is pleased to announce the full exercise of all purchase warrants issued during the company’s December 2020 private placement.

The exercise of the warrants by the investors resulted in total cash receipts of approximately $1.4 million and the issuance of 3,998,705 common shares. This marks the completion of the third round of warrant exercises in two years.

Innocan had the right to accelerate the expiry date of the warrants if the daily volume-weighted average trading price of the company’s shares on the CSE equalled or exceeded $0.70 for any period of 30 consecutive trading days.

“This remarkable achievement demonstrates a much-appreciated act of trust and confidence from our investors,” said Iris Bincovich, CEO of Innocan Pharma.

“We are excited that our investors have enjoyed the appreciation of their initial investment, and in addition they have decided to invest more. We are humbled by the continued support of our investor community, as Innocan Pharma continues to grow and secure its place as an innovator within the CBD space.”

Innocan, together with its wholly-owned subsidiary, Innocan Pharma Ltd. is a pharmaceutical tech company that focuses on the development of drug delivery platforms containing CBD.

InnoCan Pharma Corporation (INNO) opened trading at C$0.81 per share.

More From The Market Herald
Ovation Science Inc - President and CEO, Terry Howlett

" Ovation (CSE:OVAT) provides update on its topical cannabis research and development

Ovation Science (OVAT) has developed new high-dose CBD formulations for both its beauty, and health and wellness lines.
The Market Herald Video

" Adastra Holdings (CSE:XTRX) reports record third-quarter results

Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020.

" Tilray (TSX:TLRY) launches Medical Cannabis oral strips

Tilray (TLRY) makes medical cannabis oral strips powered by QuickStrip™ technology available to patients.

" InterCure (TSX:INCR.U) partners with cannabis brand Cookies

To facilitate its expansion into Europe, InterCure (INCR.U) has announced a partnership with iconic cannabis brand Cookies.